GENFIT-ADR (GNFT) Stock Overview
USA - NASDAQ:GNFT - US3722791098 - ADR
GNFT Key Statistics, Chart & Performance
The current stock price of GNFT is 4.19 USD. In the past month the price increased by 10.53%. In the past year, price decreased by -28.57%.
GNFT Latest News, Press Relases and Analysis
GNFT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.27 | 397.85B | ||
| AMGN | AMGEN INC | 13.4 | 157.32B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 146.58B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.6 | 106.83B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.46 | 69.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.75B | ||
| ARGX | ARGENX SE - ADR | 89.33 | 50.65B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.82B | ||
| NTRA | NATERA INC | N/A | 26.41B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.92B | ||
| BIIB | BIOGEN INC | 9.27 | 21.75B |
Related stock screener links
About GNFT
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
GENFIT-ADR
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE 59120 FR
CEO: Pascal Prigent
Employees: 188
Phone: 33320164000
GENFIT-ADR / GNFT FAQ
What does GNFT do?
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Can you provide the latest stock price for GENFIT-ADR?
The current stock price of GNFT is 4.19 USD. The price decreased by -0.24% in the last trading session.
What is the dividend status of GENFIT-ADR?
GNFT does not pay a dividend.
How is the ChartMill rating for GENFIT-ADR?
GNFT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in GENFIT-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNFT.
Is GENFIT-ADR (GNFT) expected to grow?
The Revenue of GENFIT-ADR (GNFT) is expected to decline by -8.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for GENFIT-ADR?
GENFIT-ADR (GNFT) currently has 188 employees.
GNFT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GNFT. When comparing the yearly performance of all stocks, GNFT is a bad performer in the overall market: 82.3% of all stocks are doing better.
GNFT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNFT. Both the profitability and financial health of GNFT have multiple concerns.
GNFT Financial Highlights
Over the last trailing twelve months GNFT reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS decreased by -327.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| Debt/Equity | 0.09 |
GNFT Forecast & Estimates
13 analysts have analysed GNFT and the average price target is 10.12 USD. This implies a price increase of 141.59% is expected in the next year compared to the current price of 4.19.
For the next year, analysts expect an EPS growth of 15.82% and a revenue growth -8.28% for GNFT